Addressing MASLD/MASH: Obstacles, Innovations, and the Future of Patient-Centric Approaches in Japan
-
By
-
Yuya Seko
-
Kanji Yamaguchi
-
April 15, 2026
Clinical Scorecard: Addressing MASLD/MASH: Obstacles, Innovations, and the Future of Patient-Centric Approaches in Japan
At a Glance
| Category | Detail |
|---|---|
| Condition | Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) |
| Key Mechanisms | Metabolic dysfunction leading to liver steatosis, inflammation, fibrosis, and progression to cirrhosis and hepatocellular carcinoma |
| Target Population | Japanese adults, including lean and obese individuals, particularly those over 50 years old |
| Care Setting | Clinical hepatology and primary care settings in Japan with integration of non-invasive diagnostic tools |
Key Highlights
- MASLD prevalence in Japan is rising, reaching approximately 25.9% in individuals over 50 years, with lean MASLD comprising about 20.7% of cases.
- Non-invasive liver disease assessment (NILDA), including vibration-controlled transient elastography (VCTE), is emerging as a key diagnostic tool, potentially replacing liver biopsy.
- Emerging therapies such as lifestyle interventions, resmetirom, and semaglutide are reshaping management, but standardized guidelines and personalized treatment strategies remain needed.
Guideline-Based Recommendations
Diagnosis
- Utilize non-invasive liver disease assessment (NILDA) techniques such as high-resolution imaging and blood-based biomarkers for early MASLD/MASH diagnosis.
- Consider liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) as a surrogate endpoint for fibrosis evaluation.
Management
- Implement lifestyle interventions focusing on diet and physical activity.
- Consider pharmacologic treatments including resmetirom and semaglutide for MASH patients.
- Adopt personalized treatment strategies accounting for patient heterogeneity and metabolic profiles.
Monitoring & Follow-up
- Regularly monitor liver fibrosis progression using non-invasive methods.
- Assess metabolic comorbidities such as diabetes, hypertension, and dyslipidemia during follow-up.
Risks
- Recognize increased risk of cardiovascular disease and chronic kidney disease in MASLD patients.
- Acknowledge higher morbidity and mortality risks in lean MASLD patients compared to non-lean counterparts.
Patient & Prescribing Data
Japanese adults with MASLD/MASH, including lean and obese subgroups
Emerging pharmacotherapies like resmetirom and semaglutide show promise; however, treatment must be individualized considering metabolic heterogeneity and comorbidities.
Clinical Best Practices
- Incorporate non-invasive diagnostic tools early to identify MASLD/MASH and fibrosis stage.
- Address metabolic risk factors comprehensively, including diabetes, hypertension, and dyslipidemia.
- Tailor treatment plans to patient-specific factors such as BMI, metabolic status, and disease severity.
- Increase clinician and public awareness of MASLD/MASH, especially in lean individuals who may be under-recognized.
- Leverage Japan’s healthcare insurance and health checkup systems to facilitate early detection and management.
Related Resources & Content
- National hepatitis control and antiviral development impact
- MASLD prevalence and epidemiology in Japan
- FDA evaluation of liver stiffness measurement
- Emerging therapies for MASH
- Global MASLD prevalence and burden
- Lean MASLD epidemiology and risks
Based on findings from:
Management of MASLD/MASH: challenges, innovations, and the future of patient-centered care in Japan
Yuya Seko, Kanji Yamaguchi. Journal Of Gastroenterology, 2026.
https://link.springer.com/article/10.1007/s00535-026-02401-9
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
